IXHL News

Incannex Healthcare, an Australian developer of synthetic cannabidiol and psychedelic medicine therapies, withdrew its plans for an initial public offering on Friday. It had most recently filed to raise $24 million by offering 2.6 million ADSs at a price of $9.38, the as-converted December 3, 2021 close of its shares on the Australian Stock Exchange (IHL). Incannex is currently...read more

Incannex Healthcare, an Australian developer of synthetic cannabidiol and psychedelic medicine therapies, announced terms for its IPO on Tuesday. The Docklands, Australia-based company plans to raise $25 million by offering 2.5 million ADSs at a price of $10, the as-converted November 19 close of its shares on the Australian Stock Exchange (IHL). At the proposed price, Incannex...read more

The IPO market is still on its August break, with just one SPAC pricing. Issuance should resume after Labor Day, and new filers are starting to flood the fall IPO pipeline, with nine initial filings this past week. Five SPACs also submitted initial filings. Waverley Capital Acquisition 1 (WAVCU) was the week’s sole pricing, raising $200 million to acquire...read more

Incannex Healthcare, an Australian developer of synthetic cannabidiol and psychedelic medicine therapies, filed on Tuesday with the SEC to raise up to $27 million. The company is currently listed on the Australian Securities Exchange (IHL). Incannex is currently conducting research and development for synthetic cannabidiol pharmaceutical products and psychedelic medicine therapies...read more